Natera (NTRA) anticipates 2025 total revenue of $1.87 billion to $1.95 billion; 2025 gross margin to be approximately 60% to 64% of revenues; selling, general and administrative costs to be approximately $950 million to $975 million; research and development costs to be $525 million to $550 million; and net cash inflow to be positive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera’s Strong Market Position and Growth Potential Drive Buy Rating Amid Expanded Medicare Coverage and Robust Patent Protections
- Natera announces Medicare coverage of Signatera test
- Is NTRA a Buy, Before Earnings?
- Natera comments on updated NCCN guidance for circulating tumor DNA
- Natera’s Promising RhD Test Developments and Revenue Growth Potential: A Buy Recommendation